GastroenterologyNEK7Lenvatinib resistance
Targeting NEK7-Mediated EGFR Phosphorylation to Overcome Lenvatinib Resistance in Hepatocellular Carcinoma
By MedXY|Aug 21, 2026
NEK7 promotes acquired lenvatinib resistance in hepatocellular carcinoma by phosphorylating EGFR at serine 1070, activating key signaling pathways. Blocking this interaction offers a promising therapeutic avenue to counteract resistance.
